quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:19:07·595d
INSIDERFiling
Kineta Inc. logo

SEC Form 4 filed by Director Bartoszek Raymond J.

KA· Kineta Inc.
Health Care
Original source

Companies

  • KA
    Kineta Inc.
    Health Care

Related

  • PR562d
    Kineta Announces Completion of Enrollment in the Monotherapy Arm of the VISTA-101 Phase 1 Clinical Study in Advanced Solid Tumors
  • PR566d
    Kineta Announces KVA12123 Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024
  • SEC568d
    Kineta Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
  • PR568d
    Kineta Announces the Extension of the TuHURA Biosciences Exclusivity and Right of First Offer Agreement for KVA12123, Kineta's VISTA blocking antibody Currently in Phase 1
  • SEC581d
    Kineta Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
  • PR581d
    Kineta, Inc Transitioning from Nasdaq to OTC Markets
  • SEC581d
    Kineta Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
  • SEC587d
    Kineta Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022